Document:

Exhibit 10.13

 

CLIP EXCLUSIVE LICENSE

 

TABLE OF CONTENTS

 

General Terms and Conditions

 

Section
1 - Novation

 

Section
2 - Definitions

 

Section
3 - Grant of Rights and
Improvements

 

Section
4 - Financial Consideration

 

Section 5 – Sublicensing

 

Section
6 - U.S. Government Rights
and Requirements

 

Section
7 - Reports, Records,
and Audits 

 

Section
8 - Proprietary Information
and Materials 

 

Section
9 - Export

 

Section
10 - Sponsored Research

 

Section
11 - Due Diligence 

 

Section
12 - Patent Prosecution

 

Section
13 - Patent Enforcement

 

Section
14 - Warranties, Indemnifications,
and Insurance

 

Section
15 - Duration, Termination,
and Conversion

 

Section
16 - General

 

Appendix
A - Patent Rights 

 

Appendix
B - Royalties 

 

Appendix
C - Due Diligence

 

Appendix
D - Diligence Reports

 

Appendix
E - Form of Royalty Report

 

Appendix
F - Material Transfer
Agreement Template

    	1 of 34

    	 

    

 

This Exclusive License
Agreement (the "Agreement") between the Regents of the University of Colorado, a body corporate, having its principal
office at 1800 Grant Street, 8th Floor, Denver, CO 80203 (hereinafter "University") and Viral Genetics, Inc., a Delaware
corporation having its principal office at 2290 Huntington Drive, Suite 100, San Marino, California 91108 (hereinafter "Licensee")
is effective on the of the 25th of August, 2009, (the "Effective Date").

 

WHEREAS University
is the owner of the Licensed Patents, as defined hereinafter, and

 

WHEREAS, University
and Licensee have previously entered into an Exclusive Licensing Agreement dated November 26, 2007 for the fields of diagnosis
and treatment of HIV, AIDS, hepatitis C, and herpes, an Exclusive Option Agreement dated May 23, 2008 for the fields of diabetes
and multiple sclerosis, and an Exclusive Option Agreement dated May 23, 2008 for twenty six other fields, each of the Agreements
being with respect to the Clip Technologies as hereinafter defined (collectively the "Prior CLIP Agreements"); and

 

WHEREAS, University
and Licensee now wish to substitute this Agreement for the Prior CLIP Agreements; and

 

NOW, THEREFORE,
in consideration of the promises and the mutual covenants contained herein, the parties hereto agree as follows:

 

GENERAL TERMS AND CONDITIONS

 

		1.	NOVATION

 

This Agreement is a novation of, and entirely replaces,
the Prior CLIP Agreements.

 

		2.	DEFINITIONS

 

For the purposes of this Agreement, the following
words and phrases shall have the following meanings:

 

		2.1	"Active Program" shall mean a developmental program advancing a
distinct diagnostic or therapeutic application covered in the Licensed Patents which is the subject of a sublicense or on which
Licensee is actively pursuing development or on which an IND Phase I, II or Ill has been issued.

 

		2.2	"Affiliate(s)" means any business entity that controls, is controlled
by, or is under common control with Licensee. Control means the direct or indirect ownership of at least fifty percent (50%).

 

		2.3	"CLIP Technologies" means the technologies described in the Licensed Patents as defined below.

 

		2.4	"Field of Use" means the diagnosis, detection, prevention, and
treatment of any disease using the CLIP Technologies.

 

		2.5	"Inventor" means Dr. Karen Newell.

 

    	2 of 34

    	 

    

 

		2.6	"Know-How" shall mean, and is limited to: (a) University's proprietary
information that has been created, developed, and fixed in any tangible medium of expression by Inventor prior to or as of the
Effective Date and which is directly related to the use of, or desirable for the practice of, the licensed Patent Rights; and (b)
University's proprietary information that is necessary for the use of, or desirable for the practice of, the licensed Patent Rights
developed by Dr. Karen Newell after the Effective Date while Dr. Newell remains an employee of University and voluntarily involved
as an employee, board member or consultant of Licensee.

 

		2.7	"Licensed Patents means the United States patents and patent applications
and invention disclosures listed in Appendix A together with any and all foreign patent applications and patents based thereon,
divisionals, continuations of those applications and the patents issued therefrom, including any reissues or reexaminations or
extensions of such patents, and claims of any continuations-in-part applications and resulting patents that are directed to subject
matter specifically described in the patents and patent applications listed in Appendix A, and any invention made during
the term of this Agreement by Dr. Karen Newell, or by anybody working in a laboratory under the supervision or direction of Dr.
Newell, that is in the Field of Use.

 

		2.8	"Licensed Process(es)" means any method, procedure, service, or
process, the practice of which, in the absence of a license, would infringe, or contribute to infringement of, a Valid Claim of
a Licensed Patent.

 

		2.9	"Licensed Product(s)" means any and all products the making, using,
importing, exporting or selling of which, in the absence of a license, would infringe, or contribute to infringement of, a Valid
Claim of a Licensed Patent.

 

		2.10	"Net Sales" means the amount of gross receipts on sales of any
Licensed Products or practice of any Licensed Processes by Licensee, Affiliates, or Sublicensees. Net Sales excludes the following
items, but only to the extent they pertain to the sale of Licensed Products or the practice of Licensed Processes, are included
in gross revenue, and are separately stated on purchase orders, invoices, or other documents of sale: (a) customary trade, quantity,
or cash discounts and non-affiliated brokers' or agents' commissions actually allowed and taken; (b) amounts repaid or credited
by reason of rejection or return; and (c) taxes levied on and other governmental charges made as to production, sale transportation,
delivery or use and paid by or on behalf of Licensee.

 

		2.11	"Sublicensee(s)" means any third party sublicensed by Licensee
to make, have made, use, have used, sell, have sold, import, have imported, exported, or have exported Licensed Product or to practice
or have practiced any Licensed Process.

 

		2.12	"Sublicense Income" shall mean any and all consideration received
by Licensee or an Affiliate from a third party as consideration for the grant of a sublicense, or an option for a sublicense, to
the Licensed Patents. Such consideration shall include without limitation any upfront, license or option initiation or signing
fees, license maintenance fees, milestone payments, equity, and research and development funding received by Licensee or Affiliate
in excess of the actual costs of performing such research and development. Sublicense Income shall also include the fair market
value of any non-cash consideration paid to Licensee for sublicense rights, Sublicense Income shall not include sums received as
royalties on Net Sales by Sublicensees, such Net Sales being subject to the royalty on Net Sales in Appendix B.

 

    	3 of 34

    	 

    

 

		2.13	"Territory" is worldwide

 

		2.14	"Valid Claim" means a pending or issued and unexpired claim of
a patent under the Intellectual Property so long as such claim has not been irrevocably abandoned or declared to be invalid in
an unappealable decision of a court or other government agency of competent jurisdiction through no fault of Licensee.

 

		3.	GRANT OF RIGHTS AND IMPROVEMENTS

 

3.1 License.
Subject to the terms and conditions of this Agreement, University grants to Licensee and its Affiliates under the Licensed Patents
an exclusive license to the Licensed Patents, and an exclusive license to the Know How, to make, have made, use, import, offer
to sell and sell Licensed Products and to practice the Licensed Process(es) in the Field of Use and Territory.

 

3.2 Reservation
of Rights. This license is expressly made subject to the University's reservation, on behalf of itself, the Inventors of the
Licensed Patents, future not-for-profit employers of such Inventors, and all other non-profit academic and research institutions,
of the right to make and use the Licensed Products and Licensed Processes under the Licensed Patents for educational, research,
or non-commercial purposes.

 

3.3 Limitation
on Rights. This Agreement confers no license or rights by implication, estoppel, or otherwise under any patent applications
or patents of University other than the Licensed Patents, regardless of whether such patents are dominant or subordinate to the
Licensed Patents.

 

3.4
Future Improvements. Provided that Dr. Newell is at the time obligated to assign intellectual property to University
and voluntarily involved as an employee, board member or consultant of Licensee , and in the event that Dr. Newell, or anybody
working in a laboratory under the supervision or direction of Dr. Newell develops any patentable invention, in the Field of Use,
which is not otherwise subject to third party obligations, and the practice of which would infringe any claim of the Licensed Patents
or Licensed Processes as if the claim is in an issued patent and in the absence of a license, ("Improvement"), then University
shall disclose each such Improvement to Licensee in reasonable written detail. All Improvements made in the Field of Use will be
considered part of this Agreement under the applicable Appendix(ces) at no additional cost to Licensee. For any other invention
made by Dr. Newell that is within the Field of Use, and is available for licensing, Licensee shall be granted, for a one time fee
of five thousand dollars ($5,000.00), a six (6) month option, beginning on the date of University's written disclosure of said
invention to Licensee, to negotiate on commercially reasonable terms license rights to add such invention to this Agreement.

 

    	4 of 34

    	 

    

 

3.5
Limits on University Ownership. Notwithstanding any other provision in this Agreement to the contrary, and whether or
not such work is in the Field of Use or outside of it, University shall not own or have (and nothing in this Agreement shall constitute
a grant of) any rights in, to or under any patents, inventions, technology, know how, or other intellectual property:

 

		3.5.1	That may be created or developed at any time by any employee of Licensee, or by Dr. Karen Newell,
working or consulting at Licensee using Licensee's own facilities, for Licensee's own account and benefit as demonstrated by written
records kept in the normal course of research and independent of her work performed or contemplated under funded research at the
University or employment agreement at the University; or

 

		3.5.2	That may be created or developed at any time by Licensee, using its own facilities, or under a
contract with, or under a grant from, a third party without any contribution from Dr. Karen Newell while Dr. Newell is at the time
obligated to assign intellectual property to University and as demonstrated by written records kept in the normal course of research.

 

3.6
University Right to Market. University shall have the right to promote and market the CLIP Technology for any use for
which Licensee is not then actively negotiating a sublicense and which is not then an Active Program. Should University successfully
deliver to Licensee a prospective sublicensee, then Licensee shall use best commercial efforts to enter into a sublicense agreement
with the sublicensee. In the event Licensee does execute a sublicense agreement with a partner delivered by University, then University's
Sublicensing Income for that agreement shall be fifty percent (50%), with a ten percent (10%) discount granted for each sublicense
already in effect, to a floor of twenty five percent (25%).

 

		4.	FINANCIAL CONSIDERATION

 

As consideration
for the license and option rights granted under this Agreement, Licensee agrees to pay to University the economic consideration
specified in Appendix B. In addition, University and License agree to the following:

 

4.1 No
Multiple Royalties. No multiple royalties shall be payable because any Licensed Products or Licensed Processes are covered
by more than one of the Licensed Patents.

 

4.2 Reduction
in Royalties. In the event that Licensee must enter into a license with a third party and agrees to pay a royalty thereunder
in order to make, use, or sell a Licensed Product or practice a Licensed Process or sublicense a Licensed Patent, then any such
royalty shall be reduced by fifty percent (50%) of the royalty paid to said third party for the same reporting period. However,
in no event shall any such royalty be less than one half the otherwise applicable royalty.

 

4.3 Sales
to Related Parties. On sales of Licensed Products by Licensee to sublicensees or on sales made in other than arm's-length transactions,
the value of the Net Sales attributed under this Section 4 to such a transaction shall
be that which would have been received in an arm's-length transaction, based on a like transaction at that time.

 

4.4
Interest. Payments past due shall bear interest at the rate of one percent (1%) per
month compounded, or the maximum interest rate allowed by applicable law, whichever is less.

 

 

    	5 of 34

    	 

    

 

4.5
Payments After License Termination. After the license terminates, Licensee will continue to submit earned royalty payments
and reports required by Section 7 of the Agreement, until all Licensed Products made
or imported under this Agreement have been sold and/or until all sublicense payments have been received by Licensee.

 

4.6 Tax-exempt.
All payments due under this Agreement shall be made without deduction for taxes, assessments, or other charges of any kind that
may be imposed on the University by any government outside of the United States or any political subdivision of such government
with respect to any amounts payable to the
University pursuant to this Agreement. All such taxes, assessments, or other charges shall be assumed by Licensee.

 

4.7
Payments. All payments to University shall be in United States Dollars, made payable to "The Regents of the University
of Colorado" and mailed to:

 

Office of Technology Transfer

University of Colorado

Suite 100, 4740 Walnut Street

Campus Box 588

Boulder, CO 80309

ATTN: Accounts Receivable

 

		5.	SUBLICENSING

 

5.1
Required Sublicense Terms. Licensee may sublicense the rights granted in Section 3.
Any sublicense granted by Licensee shall include royalty payment terms and shall be consistent with and not conflict with this
Agreement. Licensee will remain responsible for the performance of all Sublicensees under any such sublicense as if such performance
were carried out by Licensee itself, including, without limitation, the payment of any Net Sales royalties, minimum annual royalties,
milestone payments, and other license fees or payments provided for a sublicense, regardless of whether the terms of such sublicense
provide for such amounts to be paid by the Sublicensee directly to the University. Any sublicense:

 

5.1.1 Shall be subject
to the termination of this Agreement;

 

5.1.2
Will provide that any Sublicensee will not further sublicense, unless such further sublicensee agrees to all relevant terms
of this agreement mutatis mutandis;

 

5.1.3 Will expressly
include the provisions of Section 4 Financial Consideration, Section 7 Reports, Records and Audits, and Section 14 Warranties,
Indemnification, and Insurance for the benefit of the University;

 

5.1.4
State that in the event this Agreement is terminated pursuant to Section 15.2, provide for assignment of the sublicense to
University so long as the Sublicensee complies with Section 5.1 and the Sublicensee is not in breach; and

 

5.1.5
Provide only for cash or marketable securities consideration from Sublicensee(s) unless University has expressly consented
in writing and in advance to other consideration

 

5.2Sublicensee Royalties. Licensee shall
pay royalties on Net Sales by its Sublicensee(s) as specified under and on Sublicense Income as specified in Appendix
B.

 

    	6 of 34

    	 

    

 

5.3 Copy
of Sublicense and Sublicensee Reports. Licensee will submit to University a copy of each fully executed sublicense agreement
and any amendments to sublicenses granted by Licensee under this Agreement. Sublicense agreements and amendments must be postmarked
within thirty (30) days of the execution of such sublicense. Licensee will submit to University a summary and all copies of reports
provided to Licensee by Sublicensees.

 

		6.	U.S. GOVERNMENT RIGHTS AND REQUIREMENTS

 

Licensee
understands that this Agreement is subject to all of the terms and conditions of 35 U.S.C. §§ 200-212, ("The Bayh-Dole
Act") and 37 C.F.R. § 401. Licensee agrees to take all reasonable action necessary to enable University to satisfy its
obligations thereunder. Licensee shall use commercially diligent efforts to cause any Licensed Products subject to the Bayh-Dole
Act to be manufactured substantially in the United States.

 

		7.	REPORTS, RECORDS, AND AUDITS

 

		7.1	Reports. Beginning the calendar quarter
                                         after the Effective Date, Licensee shall submit to University:

 

7.1.1 Quarterly and annual
diligence reports describing Licensee's progress and plans for the development of Licensed Products. Quarterly reports may be an
oral or written (at Licensee's discretion) summary, and an annual report in written form shall be delivered to the University.
All written Diligence Reports, when used, shall conform to those as set forth in Appendix D , and Licensee shall endeavor
to include Dr. Newell whenever possible in any oral diligence report made to University. Should Licensee fall under the control
of, be acquired by or merged with another company, all reports thereafter must be in written form; and

 

7.1.2 Royalty Reports as
set forth in Appendix E for each calendar quarter beginning the first quarter in which Net Sales occurs or Sublicense Income
is received and each quarter thereafter regardless of Net Sales or Sublicense Income.

 

		7.2	Records.

 

7.2.1 Licensee shall
keep accurate records and shall compel its Affiliates and Sublicensees to keep accurate records in sufficient detail to reflect
its operations under this Agreement and to enable the royalties accrued and payable under this Agreement to be determined.

 

7.2.2 Such records shall
be retained for at least three (3) years after the close of the period to which they pertain, or for such longer time as may be
required to finally resolve any question or discrepancy raised by University.

 

		7.3	Audits.

 

7.3.1 Upon the request
of University, with reasonable notice, but not more frequently than once a year, Licensee shall permit an independent public accountant
selected and paid by University to have access during regular business hours to such records as may be necessary to verify the
accuracy of royalty payments made or payable hereunder.

 

 

    	7 of 34

    	 

    

 

 

7.3.2
Said accountant shall disclose information acquired to University only to the extent that it should properly have been contained
in the royalty reports required under this Agreement.

 

7.3.3
If an inspection shows an underreporting or underpayment in excess of five percent (5%) for any twelve (12) month period, then
Licensee shall reimburse University for the cost of the inspection and pay the amount of the underpayment including any interest
as required by this Agreement.

 

7.4
Prosecution Cost Reports. Should Licensee fall behind in required payments to the law firm it designates pursuant to
Licensee's responsibilities as set for in Section 12.1 of this Agreement such that said law firm informs University
of deficiencies in payment, then from that point forward on a semi-annual basis Licensee shall provide University with evidence
that is maintaining an appropriate fund of money as a pre-paid account with said law firm.

 

		8.	PROPRIETARY INFORMATION AND MATERIALS

 

8.1
Responsibilities. Both University and Licensee (hereinafter, "Party" or "Parties") shall vigilantly
protect any and all confidential information related to the Licensed Patents from disclosure to third parties. No such disclosure
shall be made by a Party, unless under a non-disclosure agreement commensurate with Section 8.2 to 8.5, without the written permission
of the other Party.

 

8.2
Ownership. All written documents containing confidential information and other material in tangible form received by
either Party ("Recipient") under this Agreement shall remain the property of the disclosing Party. Upon request of the
disclosing Party, the other Party shall return such documents to the disclosing Party or provide evidence of their destruction,
except that a copy may be retained for archival purposes.

 

8.3
Future information and inventions. All invention disclosures, scientific data, and business information received by
either Party under this Agreement shall be. considered cvonfidential information.

 

		8.4	Exceptions. Confidential Information shall not include:

 

8.4.1 information which
at the time of disclosure had been previously published or was otherwise in the public domain through no fault of Recipient;

 

8.4.2
information which becomes public knowledge after disclosure unless such knowledge results from a breach of this Agreement;

 

8.4.3
information which was already in Recipient's possession prior to the time of disclosure as evidenced by written records kept
in the ordinary course of business or by proof of actual use thereof;

 

8.4.4 information that
is independently developed without use of the Confidential Information; and

 

8.4.5
information which is required to be disclosed by law, court order, or government regulation.

 

 

    	8 of 34

    	 

    

8.5
CORA. Licensee acknowledges that University is subject to the Colorado Open Records Act (C.R.S. §§
24-72-201, et seq.). All plans and reports marked "Confidential" shall be treated by University as confidential
to the extent permitted under § 24-72-204.

 

8.6
Data Rights. Licensee acknowledges the University has a primary mission to secure research grants and disseminate research
results. University shall be free to use scientific and clinical data for the purposes of grant submissions and peer reviewed publication
submissions subject to the provisions of Section 3.5. Such permitted use of data shall not be delayed more than 90 days after written
disclosure to Licensee, under any circumstances.

 

8.7
Materials. University shall use a Material Transfer Agreement as attached in Appendix
F for any and all transfer of materials of any kind, including but not limited to nucleic acids, proteins, antibodies,
cells, cell culture supernatants or extracts, bodily fluids or tissues, infectious agents, or any other research reagent or compound,
from University to Licensee.

 

		9.	EXPORT

 

Licensee will not export
or re-export Licensed Patents to any country, individual, or entity except when such export or re-export is in full compliance
with the laws and regulations of the United States of America, as applicable. Applicable laws and regulations may include but are
not limited to the Export Administration Regulations, the International Traffic in Arms Regulations, and the economic sanctions
regulations administered by the U.S. Department of the Treasury.

 

		10.	SPONSORED RESEARCH

 

10.1
The Sponsored Research Agreement between the parties effective May 30, 2008 shall remain in full force and effect, with respect
to the CLIP Technologies in accordance with its terms, mutadis mutandis.

 

10.2 In
addition, Licensee shall, for the life of this Agreement, pay to University for sponsored research on CLIP Technologies, to be
governed by the terms of the May 30, 2008 Sponsored Research Agreement except for Article 3 thereof, an amount equal to the greater
of (a) ten percent (10 %) of all funds it receives from any source other than Net Sales, funds
from or resulting in debt obligation, and payment for shares in Licensee, or (b) starting April 1, 2012, twenty-five thousand dollars
($25,000.00) per quarter.

 

10.3
Notwithstanding anything to the contrary in Section 10.1 or 10.2, any payment to University for sponsored research is subject
to the requirement that Dr. Newell is employed by University at the time any such payment is due.

 

		11.	DUE DILIGENCE

 

Licensee shall use its best
efforts to bring Licensed Products and Licensed Processes to market through a thorough, vigorous and diligent program for exploitation
of the Patent Rights, to develop manufacturing capabilities, to continue active, diligent marketing efforts, and to satisfy the
needs of such market with the Licensed Products and Licensed Processes throughout the life of this Agreement. Licensee acknowledges
and agrees to the performance milestones defined in Appendix C.

 

 

    	9 of 34

    	 

    

 

		12.	PATENT PROSECUTION

 

12.1 Licensee's
Responsibilities. Licensee shall assume primary responsibility for preparing, filing and prosecuting broad patent claims for
the Licensed and Optioned Patents (including any interference or reexamination actions) for University's benefit. Within thirty
(30) days of the Effective Date, Licensee shall provide University written notice of the name of Licensee's patent counsel (or
within thirty (30) days of any change of counsel) and a copy of the engagement letter with patent counsel. Further, Licensee shall
assume primary responsibility for all patent activities, including all costs, associated with the perfection and maintenance of
Licensed Patents and shall provide University with copies of all official documents and correspondence relating to the inventorship,
prosecution, maintenance, and validity of the Licensed Patents prior to the filing of such documents. Licensee shall provide sufficient
advance notice and describe the proposed action to University before taking any actions in filing any nonprovisional patent application,
shall keep University informed of prosecution, and University shall have final approval on how to proceed with any such action.
To aid Licensee in this process, University will provide information, execute and deliver documents and do other acts as Licensee
may occasionally reasonably request. Licensee will reimburse University for University's reasonable costs in complying with such
requests. Licensee shall not abandon prosecution of any U.S. or foreign patent application without first notifying University of
Licensee's intention and reason therefore at least thirty (30) days prior to any bar date and providing University with . reasonable
opportunity to assume responsibility for prosecution, maintenance of such patents and patent applications.

 

12.2 Foreign
Patent Prosecution. If Licensee will not pursue patents in a foreign country where patent protection may be available, Licensee
shall notify the University thirty (30) days prior to any patent prosecution bar date in that country so that University may prosecute
patents in that country if University so desires. If University pursues such foreign patent protection, then from that time forward
all such patent applications and any patents arising therefrom shall not be considered Licensed Patents under this Agreement and
Licensee shall forfeit any and all rights under this Agreement to such patent applications and any patents arising therefrom. University
shall be responsible for all costs associated with those patent applications and patents it decides to pursue and maintain.

 

12.3 University's
Right to Resume Prosecution. At any time, University may provide Licensee with thirty (30) days written notice that University
wishes to resume control of the preparation, filing, prosecution, and maintenance of any and all patent applications or patents
included in the Licensed Patents. If University elects to resume such responsibilities, Licensee agrees to cooperate fully with
University, its attorneys, and agents in the preparation, filing, prosecution, and maintenance of any and all patent applications
or patents and to provide University with complete copies of any and all documents or other materials that University deems necessary
to undertake such responsibilities. Licensee shall have the right to omit any such patent application or patent from Licensed Patents
of Section 2.7. Licensee shall reimburse University within 30 days of receiving an invoice from University for patent prosecution
expenses for Licensed Patents incurred by University after the University has resumed prosecution.

 

    	10 of 34

    	 

    

 

		13.	PATENT ENFORCEMENT

 

13.1Notice
of Infringement. University and Licensee agree to inform the other Party promptly in writing of any suspected infringement
of the Licensed Patent(s) by a third party. Such notice shall
include any evidence of infringement possessed by the suspecting Party. Upon such notice and before proceeding with any action
(e.g., cease and desist notice), the parties shall consult with each other before Licensee proceeds with any action.

 

13.2 University
Suit. University shall have the first right to institute suit, and may name Licensee for standing purposes. If University decides
to institute suit, it will provide written notice to Licensee within 90 days of the date when a party receives notice of infringement.
If within 45 days of such notice, Licensee does not notify University in writing that it will jointly prosecute the suit, Licensee
will assign and hereby does assign to University all rights, causes of action, and damages resulting from the alleged infringement.
University will bear the entire cost of the litigation and will retain the entire amount of any recovery or settlement.

 

13.3
Joint Suit. If University and Licensee agree to institute suit jointly, the suit shall be brought in both their names,
the out-of-pocket costs thereof shall be borne equally, and any recovery or settlement shall be shared equally. University and
Licensee shall agree to the manner in which they shall exercise control over such suit. Each Party, at its option, may be represented
by separate counsel of its own selection, the fees for which shall be paid by each such party.

 

13.4
Licensee Suit. In the absence of an agreement to institute a suit jointly, and if University either notifies Licensee
that it does not intend to pursue legal action or does not notify Licensee of its intent to pursue legal action as provided in
Sections 13.2 within ninety (90) days of the notice of infringement, Licensee may institute suit. Licensee agrees to keep University
reasonably apprised of the status and progress of any litigation. Licensee shall bear the entire cost of such litigation. Any recovery
shall first be applied to the reimbursement, on a pro-rata basis according to the amounts to be reimbursed, of the royalties withheld
pursuant to Section 13.5 and Licensee's and University's reasonable attorneys fees for outside counsel and court costs incurred
in litigation related to enforcement of the Licensed Patents. Any remaining recovery shall be subject to (i)
the then-applicable sublicense royalty to the extent the damage award is based on lost sublicense income or lost profits
due to the infringing sales, and (ii) the earned royalty to the extent that the damage award
is based on lost Net Sales.

 

13.5
Litigation Cost Offset. If Licensee undertakes to defend the Patent Rights by litigation, Licensee may deduct from its
royalty payments to University with respect to the Patent Rights subject to suit an amount not exceeding fifty (50%) of Licensee's
expenses and costs of such action, including reasonable attorney's fees, provided however, that such reduction shall not exceed
fifty percent (50%) of the total royalty due to University for each calendar year.

 

		14.	WARRANTIES, INDEMNIFICATIONS, AND INSURANCE

 

14.1 Negation
of Warranties. University makes no representations, extends no warranties of any kind, either express or implied, and assumes
no responsibilities whatsoever with respect to use, sale, or other disposition by Licensee or its sublicensee(s), Affiliates,
or vendees or other transferees of Licensed Products or licensed Processes incorporating or made by use of the Licensed Patents,
know-how or optioned intellectual property rights. There are no express or implied warranties of merchantability or fitness for
a particular purpose, or that the use or sale of such products or processes will not infringe any patent, copyright, trademark,
service mark, or other rights. Nothing in this Agreement shall be construed as

 

    	11 of 34

    	 

    

 

(1) A warranty or representation
by University as to the validity or scope of any of the rights included in the Licensed Patents;

 

(2) A warranty or representation
that the Licensed Patents or anything made, used, sold or otherwise disposed of under the License will or will not infringe patents,
copyrights or other rights of third parties;

 

(3) An obligation to furnish
any know-how or services not agreed to in this Agreement, or

 

(4) An obligation by the
University to bring or prosecute actions or suits against third parties for infringement, or to provide any services other than
those specified in this Agreement.

 

14.2
Indemnification. Licensee shall indemnify, defend, and hold University, its regents, employees, students, officers,
agents, affiliates, representatives, and inventors ("University Indemnities") harmless from and against all liability,
demands, damages, losses, and expenses (including attorney fees), for death, personal injury, illness, property damage, noncompliance
with applicable laws and any other claim, proceeding, demand, expense and liability of any kind whatsoever in connection with or
arising out of:

 

(1) the use by or on behalf
of Licensee, its sublicensees, Affiliates, directors, officers, employees, or third parties of any Licensed Patents;

 

(2) the design, manufacture,
production, distribution, advertisement, consumption, sale, lease, sublicense or use of any Licensed Product(s), Licensed Process(es)
or materials by Licensee, or other products or processes developed in connection with or arising out of the Licensed Patents; or

 

(3) any right or obligation
of Licensee under this Agreement.

 

14.3 Insurance.
Licensee warrants that, except for obligations relating to any human trial until a human trial is undertaken, it now maintains
and will continue to maintain Comprehensive General Liability Insurance, including Product Liability Insurance, and any other insurance
customary in the industry, and that such insurance coverage lists University and the University Indemnities as additional insureds.
Within ninety (90) days after the execution of this Agreement and thereafter on January 15 of each year, Licensee will present
evidence to University that the coverage being maintained with University and the University Indemnities listed as additional insureds.
In addition, Licensee will provide University with at least thirty (30) days prior written notice of any change in or cancellation
of insurance coverage.

 

		15.	DURATION, TERMINATION, AND CONVERSION

 

15.1 Term.
This Agreement shall become effective as of the Effective Date and shall expire on the expiration date of the last to expire patents
within the Licensed Patents or Intellectual Property Rights.

 

15.2 Termination
by Licensee. Licensee may terminate this Agreement in its entirety, if Licensee:

 

(1) Pays all amounts due as well
as all non-cancelable costs to University through the termination date;

 

    	12 of 34

    	 

    

 

(2) Submits final payments with
interest as provided in Section 4.4 and a final report of the type described in Section 7;

 

(3) Returns any confidential materials
provided to Licensee by University in connection with this Agreement;

 

(4) Suspends its use and sales
of the Licensed Product(s) and Licensed Process(es); provided however, that subject to making the payments required by Section
4 and the reports required by Section 7, Licensee may, for a period of ninety (90) days after the effective date of such termination,
sell all Licensed Products which may be in inventory; and

 

(5) Provides University the
right to access any regulatory information filed with any U.S. or foreign government agency with respect to Licensed Products and
Licensed Processes.

 

15.3 University
may terminate the relevant portion of this Agreement if Licensee: (1) Is delinquent on any report or payment that is not in dispute;
is in breach of the diligence obligations described in Appendix B or C, including the
milestone requirements and such missed milestone is not otherwise excused pursuant to the ·terms of this Agreement; provides
any false report, as determined by Section 16.8 Dispute Resolution of this Agreement, or is in breach of any other material provision
of this Agreement, and fails to cure any of these circumstances within 30 days of University's written notice to Licensee;

 

(2) Violates any laws or regulations
of applicable governmental entities;

 

(3) Becomes insolvent, defined
by the voluntary filing of a Chapter 7 proceeding under the Bankruptcy Law, or if Licensee shall cease to carry on its business
or development activities pertaining to Licensed Patents; or

 

(4) Institutes a legal action
challenging the validity of any Licensed Patent.

 

15.4 Other
Termination. The exclusive license granted by this Agreement shall terminate if a non-voluntary Chapter 7 proceeding under
the Bankruptcy Law is filed that is not dismissed prior to liquidation. The exclusive license shall NOT pass to a trustee in a
Chapter 7 bankruptcy or be held as an· asset of said Chapter 7 bankruptcy.

 

		16.	GENERAL

 

16.1Assignment.
This Agreement shall be binding upon and inure to the benefit of the respective successors and assigns of the Parties hereto.

 

16.1.1 Subject to Section
16.1.3, Licensee may assign this Agreement as part of a sale, regardless of whether such a sale occurs through an asset sale, stock
sale, merger or other combination, or any other transfer of (i) Licensee's entire business; or (ii) that part of Licensee's business
that exercises all rights granted under this Agreement.

 

16.1.2 Any other attempt
to assign this Agreement by Licensee is null and void.

 

 

    	13 of 34

    	 

    

 

 

16.1.3 Prior to any assignment,
the following conditions must be met: (i) Licensee must give University ten (10) days prior written notice of the assignment, including
the new assignee's contact information; and (ii) the new assignee must agree in writing to University to be bound by this Agreement.

 

16.1.4 In the event of a
bankruptcy, assignment is permitted only to a party that can provide adequate assurance of future performance, including diligent
development and sales, of Licensed Patents.

 

		16.2	Notice.

 

16.2.1 Licensee will provide
written notice to University at least ninety (90) days prior to bringing an action seeking to invalidate any Licensed Patent or
a declaration of non-infringement. Licensee will include in such written notice an identification of all prior art it believes
invalidates any claim of the patent.

 

16.2.2 Notice hereunder shall
be deemed sufficient if given by registered mail, postage prepaid, and addressed to the Party to receive such notice at the address
given below, or such other address as may hereafter be designated by notice in writing. All general notices to Licensee shall be
mailed to:

Haig Keledjian, President and CEO Viral Genetics,
Inc.

2290 Huntington Drive, Suite 100

San Marino, California 91108

 

16.2.3 All financial invoices
to Licensee (i.e., accounting contact) shall be mailed to

 

16.2.4 All general notices
to University shall be e-mailed or mailed to: License

 

Administrator

Office of Technology Transfer

University of Colorado, 588 SYS

4740 Walnut Street

Boulder, CO 80309

 

16.2.5 Either party may change its mailing or
e-mail address with written notice to the other party.

 

    	14 of 34

    	 

    

 

16.3 Use
of Names and Marks. Licensee agrees not to identify University in any promotional advertising, press releases, sales literature
or other promotional materials to be disseminated to the public or any portion thereof without University's prior written consent
in each case, except that Licensee may state that it has a license for the Licensed Patents from University. University may state
that it has a license for the Licensed Patents with the Licensee. Licensee further agrees not to use the name of University or
any University faculty member, inventor, employee or student or any trademark, service mark, trade name, copyright or symbol of
University, without the prior written consent of the University, entity or person whose name is sought to be used. Notwithstanding
the foregoing, Licensee or shareholders of Licensee, including Viral Genetics, Inc., may be obligated under applicable law or have
a bonafide interest in identifying University, Licensee and this Agreement through public disclosures, filings, press releases
and other media. University acknowledges and agrees to such disclosures, provided that it has two (2) business days to review such
disclosures in advance. Any such disclosure shall be redacted to exclude information that is sensitive and may reasonably prejudice
the competitive position, future negotiations, or other competitive factors of Licensee, University, or Viral Genetics, Inc.

 

16.4
Marking. Licensee agrees to cause Licensed Products or the product of Licensed Processes sold under this license to
be marked with the notice of the patent numbers or patent pending, as may be appropriate.

 

16.5 University
Rules and Regulations. Licensee acknowledges that University employees who are engaged by Licensee, whether as consultants, employees,
or otherwise, or who possess a material financial interest in Licensee, are subject to the University's rule regarding outside
activities and financial interests as set forth in the University's intellectual property policy and related policies regarding
conflicts of interest and outside consulting, as may be amended from time to time. Any term or condition of an agreement between
Licensee and a University employee that seeks to vary or override such employee's obligations to the University may not be enforced
against such personnel or the University without the express written consent of the Principal Technology Transfer Officer.

 

16.6
Compliance with the Law. Licensee shall comply with all commercially material local, state, federal, and international
laws and regulations relating to its obligations under this Agreement regarding the development, manufacture, use, and sale of
Licensed Products and Licensed Processes.

 

16.7
Choice of Law. This Agreement shall be governed by and construed in accordance with the laws of the State of Colorado.

 

16.8
Dispute Resolution. In the event of any dispute arising out of or relating to this Agreement, the affected Party shall
promptly notify the other Party ("Notice Date"), and the Parties shall attempt in good faith to resolve the matter.

 

16.8.1 Any disputes
not so resolved shall be referred to the Principal Technology Transfer Officer for the University and to Licensee's senior executives
with settlement authority ("Senior Executives"), who shall meet at a mutually acceptable time and location within thirty
(30) days of the Notice Date and shall attempt to negotiate a settlement.

 

16.8.2 If the Senior
Executives fail to meet within thirty (30) days of the Notice Date, or if the matter remains unresolved for a period of sixty (60)
days after the Notice Date, the Parties hereby irrevocably submit to the jurisdiction of a court of competent jurisdiction in the
State of Colorado, and, by execution and delivery of this Agreement, each (i) accepts, generally and unconditionally, the jurisdiction
of such court and any related appellate court, and (ii) irrevocably waives any objection it may now or hereafter have as to the
venue of any such suit, action or proceeding brought in such court or that such court is an inconvenient forum.

 

 

    	15 of 34

    	 

    

 

16.9 Modification
of Agreement. The terms and provisions contained in this Agreement constitute the entire Agreement between the Parties and
shall supersede all previous communications, representations, agreements or understandings, either oral or written, between the
Parties hereto with respect to the subject matter hereof, and no agreement or understanding varying or extending this Agreement
will be binding upon either Party hereto, unless in a written amendment to this Agreement signed by duly authorized officers or
representatives of the respective Parties, and the provisions of this Agreement not specifically amended thereby shall remain in
full force and effect according to their terms.

 

16.10 Severability.
The provisions and clauses of this Agreement are severable, and in the event that any provision or clause is determined to be invalid
or unenforceable under any controlling body of the law, such invalidity or unenforceability will not in any way affect the validity
or enforceability of the remaining provisions and clauses hereof.

 

16.11 Scope.
This Agreement does not establish a joint venture, agency or partnership between the Parties, nor create an employer- employee
relationship.

 

16.12 Preservation
of Immunity. The Parties agree that nothing in this Agreement is intended or shall be construed as a waiver, either express
or implied, of any of the immunities, rights, benefits, defenses or protections provided to University under governmental or sovereign
immunity laws from time to time applicable to University, including, without limitation, the Colorado Governmental Immunity Act
(C.R.S. § 24-10-101, et seq.) and the Eleventh Amendment to the United States Constitution.

 

16.13 Headings.
Headings are included herein for convenience only and shall not be used to construe this Agreement.

 

16.14 Survival.
The provisions of Sections 4 Financial Consideration; 7 Reports, Records, and Audits, 8 Proprietary Information and Materials;
14 Warranties, Indemnifications, and Insurance; 16.3 Use of Names and Marks; 16.7 Choice of Law; 16.12 Preservation of Immunity;
and 16.14 Survival and any other provision of this Agreement that by its nature is intended to survive, shall survive any termination
or expiration of this Agreement.

 

 

IN WITNESS WHEREOF
the parties hereto have caused this Agreement, to be executed in duplicate by their respective duly authorized officers.

 

 

 

    	16 of 34

    	 

    

APPENDIX A

Patent Rights

 

 

Invention Disclosures

 

CU1760C- Selective
Modulation of Gamma Delta T Cells to Treat Autoimmune Diseases, HIV, and Cancer

 

CU1969C - Competitive inhibitors of Invariant
Chain expression and/or ectopic CLIP binding

 

CU1971C- Use of soluble
H-2M (HLA-DM) as a CLIP displacement therapy (combined with CU1969C and patents filed under CU1969C)

 

CU2131C- Topical HIV
prevention cream/gel (provisional application was abandoned as it was covered under applications filed in CU1760C and CU1969C)

 

CU2253C - The use
of non-specific CLIP displacing peptides to treat or prevent chronic disease mediated by infectious organisms (no patents filed
yet)

 

CU2254C - The use of
peptides derived from an infectious organism that displace CLIP in order to treat or prevent chronic conditions mediated by those
very organisms (no patents filed yet)

 

Patent Applications

 

	Country	Serial No	File Date	Title	lnternal
    ID
	United States	60/886,852	01/26/2007	Methods of Modulating Immune Function Through Targeting of Invariant Chain/CD74 and Clip	CU1760C- PPA1
	United
States	60/906,731	03/13/2007	Immune Mechanism For The Depletion of CD4+ T Cells	CU1760H- PPA2
	PCT	PCT/US2008/001097	01/28/2008	Methods of Modulating Immune Function	CU1760C- PCT1
	United States	12/011,643	01/28/2008	Methods of Modulating Immune Function	CU1760C-US2
	United States	12/021'118	01/28/2008	Methods of Modulating Immune Function	CU1760C-US1
	United
States	61/191,740	09/11/2008	The Immune Response to HIV	CU1760C- PPA3

 

 

 

    	17 of 34

    	 

    

 

Patent Applications Cont.

 

	Country	Serial No	File Date	Title	lnternal
    ID
	United States	61/000,152	10/23/2007	Competitive
    Inhibitors of Invariant Chain Expression and/or Ectopic Clip Binding	CU1969C- PPA1
	United
States	61/135,942	07/25/2008	Clip
    Inhibitors and Methods of Modulating Immune Function	CU1969C- PPA2
	United States	61/135,964	07/25/2008	Competitive
    Inhibitors of Invariant Chain Expression and/or Ectopic Clip Binding	CU1996C- PPA3
	United States	61/137,150	07/25/2008	Methods
    for Treating Viral Disorders	CU1969C-PPA4
	PCT	PCT/US2008/012078	10/23/2008	Competitive
    Inhibitors of Invariant Chain Expression and/or Ectopic Clip Binding	CU1969C-PCT1
	United
States	15/508,554	07/23/2009	Methods
    for Treating Viral Disorders	CU1969C- US1
	PCT	Pending	7/23/2009	Methods For Treating Viral Disorders	CU1969C-PCT3
	PCT	Pending	7/23/2009	Clip Inhibitors and Methods of
    Modulating Immune Function	CU1969C-PCT2
	United States	12/508,543	7/23/2009	Clip Inhibitors and Methods of
    Modulating Immune Function	CU1969C-US2
	United States	61/135,922	7/25/2008	Proteins for Use in Diagnosing
    and Treating Infection and Disease	CU2421H-PPA1
	United States	12/508,532	7/23/2009	Proteins for Use in Diagnosing
    and Treating Infection and Disease	CU2421H-US1
	PCT	Unknown	7/23/2009	Proteins for Use in Diagnosing
    and Treating Infection and Disease	CU2421H-PCT1

 

  

    	18 of 34

    	 

    

 

APPENDIX B Royalties

 

Minimum annual royalty:

 

Twenty Five Thousand Dollars ($25,000.00)
in each calendar year thereafter until first commercial sales occur.

 

Seventy Five Thousand Dollars ($75,000.00)
in each calendar year after first commercial sales occur.

 

Earned royalty:

 

Three Percent (3.0%) of Net Sales from
sales in developed countries, and One Half Percent (0.5%) from sales in undeveloped countries. Developed countries are herein defined
as United States of America, Canada, Western and Eastern Europe, Japan, Australia, New Zealand, Israel, Russia, and other countries
of the former Soviet Union, Hong Kong, Singapore, South Korea, and Taiwan. Undeveloped countries are herein defined as countries
other than developed countries.

 

Benchmark royalties as follows:

 

Provided that a patent has issued on the
subject matter, the following amounts shall be paid to University within ninety (90) days of the following events, where "indication"
refers to the use of a drug for treating a particular disease:

 

	1. 	Thirty Five Thousand Dollars ($35,000.00) upon acceptance of each Investigational New Drug Application (INDA) with the Food and Drug Administration (FDA) or with the European Agency for the Evaluation of Medicinal Products (EMEA)
	 	 
	2. 	One Hundred Thousand Dollars ($100,000.00) within ninety (90) days of each first indication at the initiation of Phase I.
	 	 
	3. 	Two Hundred Thousand Dollars ($200,000.00) within ninety (90) days of each first indication at the initiation of Phase II
	 	 
	4. 	Three Hundred Thousand Dollars ($300,000.00) within ninety (90) days of each first indication at the initiation of Phase Ill.
	 	 
	5. 	Five Hundred Thousand Dollars ($500,000.00) within ninety (90) days of FDA approval of a first indication.
	 	 
	6. 	One-half of all aforementioned milestones for each second and subsequent indications.

 

Payment of sublicensing royalties
as follows:

 

Sublicensing royalties payable to the University
shall be, with respect to each sublicense, in accordance with the following:

 

	1.	For sublicense agreements executed within the first twelve (12) months, fifty percent (50%) of
Sublicense Income.

	2.	For sublicense agreements executed in the second and third years after the Effective Date, thirty-five
percent (35%) of Sublicense Income.

	3.	For sublicense agreements executed after the third year after the Effective Date, twenty percent (20%) of Sublicense Income.

 

 

    	19 of 34

    	 

    

 

APPENDIX
C

 

Due Diligence

 

Licensee
shall use commercially reasonable efforts to develop, manufacture, market and sell the Licensed Products and Licensed Processes
in the Field of Use and Territory in accordance with the below milestones.

 

a.      Licensee shall show
evidence of the initiation of at least three (3) Active Programs in the therapeutic fields within three (3) years from the Effective
Date.

 

b.      On or before six months from the Effective Date of this Agreement, Licensee shall secure at least half time employment of an
officer level employee, or engage a senior outside consultant, with drug development experience to oversee clinical trials in the
Field of Use.

 

c.      Licensee shall reach
a pre-clinical stage by September 15, 2010.

 

d.      Licensee shall file
its first IND by September 15, 2011.

 

e.       Licensee shall
be at Phase I by September 15, 2012.

 

f.      Licensee shall be at
Phase Ill by September 15, 2015, but shall be afforded more time if such is due to the nature of the requirements met in Phase
I or II.

 

 

    	20 of 34

    	 

    

 

APPENDIX D

 

Diligence Report

 

Licensee shall submit the Diligence Report and mark it as confidential
as provided in Section 7 of the Agreement. The Diligence Report shall include the following:

 

	a.	Date development plan initiated and time period
covered by this report.

 

	b.	Development Report (4-8 paragraphs)

 

1. Activities completed
since last report including the object and parameters of the development, when initiated, when completed and the results.

 

2. Activities currently
under investigation, i.e., ongoing activities including object and parameters of such activities, when initiated, and projected
date of completion.

 

		c.	Future development activities (4-8 paragraphs)

 

1. Activities to be
undertaken before next report including, but not limited to, the type and object of any studies conducted and their projected starting
and completion dates.

 

2.Estimated total development
time remaining before a product will be commercialized.

 

		d.	Changes to initial development plan (2-4 paragraphs)

 

1. Reasons for change.

 

2. Variables that may cause
additional changes.

 

3. Rationale for delay in
or termination of development plans or product lines, including financial, strategic, and legal reasons.

 

4. Rationale for non-termination
of Agreement or retention of Field of Use

 

		e.	Items to be provided if applicable:

 

1. If the Licensee receives
funding from the State of Colorado, including funds received through the University of Colorado, Licensee shall provide a summary
of capital investments and an employee growth chart(# of FTEs, etc.)

 

2.Information relating to
Product that has become publicly available, e.g., published articles, competing products, patents, etc.

 

3. Development work being
performed by third parties other than Licensee to include name of third party, reasons for use of third party, planned future uses
of third parties including reasons why and type of work.

 

4. Update of competitive
information trends in industry, government compliance (if applicable) and market plan.

 

5. Information and copies
of relevant materials evidencing the status of any patent applications or other protection relating to Licensed Products, Licensed
Processes, or the Licensed Patents.

 

 

 

    	21 of 34

    	 

    

 

APPENDIX E

 

Form of Royalty Report

 

 

 

    	22 of 34

    	 

    

 

APPENDIX F

 

Material Transfer Agreement Template

 

 

THIS
MATERIAL TRANSFER AGREEMENT, together with its Attachments, (the "Agreement") is made and entered into this
of , 20 (the "Effective Date") by and between the Regents of the University of Colorado, a body corporate, having its
principal office at 1800 Grant Street, 8th Floor, Denver, CO 80203 (hereinafter "University") and the Institution receiving
the Material, the "Recipient").

 

WHEREAS, University
possesses certain materials as specified in Exhibit A attached hereto and more
specifically defined herein;

 

WHEREAS,
Recipient is conducting the specific research activities described in the Research Plan set forth in Exhibit
A (the "Research"), at Recipient's facilities (the "Facility"); and

 

WHEREAS,
University desires to supply, and Recipient desires to obtain, samples of the Materials solely for use by the Investigator
(as defined herein) in the Research in accordance with the terms and conditions of this Agreement; ·

 

NOW
THEREFORE, to protect University's proprietary interests with respect to the Materials, University agrees to provide
Materials to Recipient for the purposes of conducting the Research, subject to the following terms and conditions:

 

 

SECTION 1. DEFINITIONS

 

		1.1	"Commercial
Purposes" shall mean the sale, lease, license, or other transfer of the Material or Modifications to a for-profit organization.
Commercial Purposes shall also include uses of the Material or Modifications by any organization, including Recipient, to perform
contract research, to screen compound libraries, to produce or manufacture products for general sale, or to conduct research activities
that result in any sale, lease, license, or transfer of the Material or Modifications to a for-profit organization. However,
industrially sponsored academic research shall not be considered a use of the Material or Modifications for Commercial Purposes
per se, unless any of the above conditions of this definition are met.

 

		1.2	"Material" or "Materials" shall mean all material provided
to Recipient, Progeny, Unmodified Derivatives, and any modification to Material, if such modified Material is substantially based
on or incorporates a substantial element of original Material), or any modification that is not new or not obviously distinct from
the original Material.

 

		1.3	"Modifications" shall mean substances created by Recipient that
do not contain/incorporate the Material.

 

		1.4	"Progeny" shall mean unmodified descendant from the Material,
such as virus from virus, cell from cell, organism from organism.

 

 

    	23 of 34

    	 

    

 

		1.5	"Unmodified Derivatives" shall mean substances created by Recipient
that constitute an important unmodified functional sub-unit of the Original Material. Examples of Unmodified Derivatives include,
but shall not be limited to, subclones of unmodified cell lines, purified or fractionated sub-sets of the original Material when
those were known to University, proteins expressed by RNA/DNA supplied by University, DNA/RNA sequences for a protein with an activity
known to or suspected by University, monoclonal antibodies secreted by a hybridoma cell line, sub-sets of the Original Material
such as novel plasmids or vectors.

 

SECTION 2. OWNERSHIP, USE AND TRANSFER

 

		2.1	Ownership
of Material:Legal title to the Material shall remain with University. Nothing in this Agreement grants any rights under
any patents or in any know-how of University nor any rights in the Material or any product or process related thereto or derived
therefrom other than those rights specifically set forth herein. Except as expressly provided in this Agreement, no rights are
provided to Recipient under any patents, patent applications, copyrights, trade secrets or other proprietary rights of University.
In particular, no rights are provided to use the Material or any related patents of University for any profit-making or Commercial
Purposes.

  

		2.2	Use of
                                         Material: University will use commercially reasonable efforts to provide Recipient
                                         with the quantity of the material described in Exhibit A. Recipient will
                                         use the Material exclusively for the non-commercial research described in Exhibit
                                         A and for no other purpose. The Research will be conducted
                                         solely by or under the direction of the designated investigator at Recipient's research
                                         facilities (the "Investigator"). In addition, Recipient shall only allow employees
                                         and agents under its direct control and supervision to have access to the Material. Recipient
                                         will not use the Material for testing in or treatment of human subjects. Recipient agrees
                                         to use the Material in compliance with all applicable laws, governmental regulations,
                                         and guidelines. The Material will not be distributed further to third parties for any
                                         purpose without the prior written consent of University.

 

		2.3	Transfer of Material:

 

		a.	Recipient shall have the right, without restriction, to distribute substances
created by Recipient through the use of the Material only if those substances do not include the Material or Modifications that
incorporate the Material. Recipient shall not attempt to reverse engineer, deconstruct, or in any way determine the structure or
composition of the Material.

 

		b.	Upon written permission from University, Recipient may distribute Modifications
that incorporate Material for commercial use. It is recognized by Recipient that such commercial use may require a license from
University and University has no obligation to grant such a license. Nothing in this paragraph, however, shall prevent Recipient
from granting commercial licenses under Recipient's patent rights claiming Modifications as defined herein.

 

 

    	24 of 34

    	 

    

 

SECTION 3. INVENTIONS

 

		3.1	Tangible Property: Ownership of tangible property between University and Recipient, as may or may not be applicable,
is defined in Exhibit A.

 

		3.2	Disclosure: Recipient will promptly and fully disclose in writing
to University any and all Inventions (as defined herein), know-how and other rights (whether or not protectable under state, federal,
or foreign intellectual property laws) related to the Material or its use, or developed using the Material, which are conceived
and/or reduced to practice by Recipient, alone or jointly with others, in the course of its research (the "Inventions").
Recipient shall be free to file patent applications claiming Inventions made through the use of the Material but agrees to notify
University in advance of such filing if it files patent applications claiming Modifications that incorporate or use the Material
in any way.

 

		3.3	lnventorship: lnventorship shall be determined according to U.S. patent law.

 

		3.4	Joint Inventions: Any patent applications necessary to protect the
proprietary positions of the parties in any Inventions made jointly by University and Recipient shall be prepared, filed and prosecuted
by University, jointly in its and Recipient's names, with expenses shared equally by the parties. If University elects not to prepare,
file, prosecute or maintain an application or patent arising from any joint Invention, University shall promptly notify Recipient,
and Recipient shall have the right to prepare, file, prosecute and maintain such applications or patents, in Recipient's and University's
names, and at Recipient's expense. Subject only to Recipient's grant of an option to University under Section 4, each of University
and Recipient's shall have the right to license, transfer, and/or sell its rights in such joint inventions without the consent
of the other.

 

		3.5	Recipient's Sole Inventions: Any patent applications necessary to protect
the proprietary positions of the parties in any Inventions made solely by Recipient shall be prepared, filed and prosecuted by
Recipient, solely in Recipient's name, with the expenses paid by Recipient. If Recipient elects not to prepare, file, prosecute,
or maintain an application or patent arising from any sole Inventions, Recipient shall promptly notify University, and University
shall have the right to prepare, file, prosecute, and maintain such applications or patents, in Recipient's name and at University's
expense. In return for University's support of patent prosecution and maintenance, the parties agree to good faith negotiation
regarding University's share of any and all consideration received under any licenses resulting from such patentable subject matter.

 

		3.6	Patent
Cooperation:Each party shall provide the other party with copies of all substantive communications from all patent offices
regarding applications or patents on any joint Inventions and Recipient's sole Inventions promptly after the receipt thereof.
Each party shall provide the other party with copies of all proposed substantive communications to such patent offices regarding
applications or patents on any such Inventions in sufficient time before the due date in order to enable the other party an opportunity
to comment on the content thereof. Each party shall make available to the other party or its authorized attorneys, agents, or
representatives, such of its employees whorn the other party in its reasonable judgment deems necessary in order to assist it
in obtaining patent protection for such Inventions. Each party shall sign or use its best efforts to have signed all legal
documents necessary to file and prosecute patent applications or to obtain or maintain patents at no cost to
the other party.

 

    	25 of 34

    	 

    

 

		3.7	Reimbursement of Patent Expenses: In the event University exercises
its option and executes an exclusive license to Recipient's interest in an Invention under Section 4 herein, University shall reimburse
Recipient for its reasonable patent expenses related to such Invention and thereafter, the prosecution and maintenance of such
patent applications and patents shall be as provided in the license agreement.

 

 

SECTION 4. COMMERCIAL USE

 

		4.1	Option for Exclusive License: Recipient hereby grants to University
an option to obtain an exclusive, royalty-bearing license to Recipient's interests in all Inventions. For each Invention, University's
option must be exercised within ninety (90) days of the written disclosure of that Invention to University by Recipient. The royalty
rates payable for the exclusive license to such Inventions, together with the other terms thereof, will be negotiated by the parties
in good faith. If any prior agreements between Recipient and a third party would preclude Recipient from granting an exclusive
license to University, then such license shall include the broadest possible rights
licensable to University.

 

		4.2	Commercial License to Material: If Recipient desires to use the Material
for profit making or commercial purposes, Recipient agrees, in advance of such use, to negotiate in good faith with University
to establish the terms of a commercial license. It is understood by Recipient that University shall have no obligations to grant
such a license to Recipient, and may grant exclusive or non-exclusive commercial licenses to others. In consideration of University's
supporting those costs and supplying the Material, Recipient hereby grants University a ninety (90) day period (after the filing
of a US patent application claiming the Invention or Modification or after the supply of a sample of the Modification if no patent
application is to be filed) to negotiate the terms of a worldwide commercial license. Such a license shall include a reasonable
royalty based on the respective parties' contributions and relevant industry standards and, subject to University's policies, shall
include such terms as are typical in licenses of similar technology from non profit organizations to for-profit organizations.

 

 

SECTION 5. NOTIFICATION OF RISKS

 

		5.1	University shall inform Recipient of any toxicity, health risks, etc. associated
with the Material that are reasonably known to University. Recipient's Investigator
shall inform University of any toxicity, health risks, etc. discovered through the use of the Material.

 

 

    	26 of 34

    	 

    

 

SECTION 6. WARRANTIES, INDEMINFICATION, INSURANCE

 

		6.1	Any Material delivered pursuant to this Agreement is understood to be experimental
in nature, and will be used with prudence and appropriate caution, since not all of its characteristics are known.

 

		6.2	Negation of Warrantees: UNIVERSITY MAKES NO REPRESENTATIONS AND EXTENDS
NO WARRANTIES, EITHER EXPRESS OR IMPLIED. THE MATERIAL IS PROVIDED WITHOUT WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR
PURPOSE OR ANY OTHER WARRANTY, EXPRESS OR IMPLIED OR THAT THE USE OF THE BIOLOGICAL MATERIALS WILL NOT INFRINGE ANY PATENT, COPYRIGHT,
TRADEMARK, OR ANY OTHER PROPRIETARY RIGHT.

 

		6.3	Indemnification: Recipient agrees to indemnify University for liability,
loss, or damage they may suffer as a result of claims, demands, costs or judgments against University arising out of the activities
to be carried out pursuant to this Agreement.

 

		6.4	Insurance: Recipient shall obtain general liability insurance, including
product liability insurance, on such terms and in such amounts as are reasonable and customary within its industry.

 

 

SECTION 7. RECIPIENT'S ASSUMPTION OF LIABILITY

 

		7.1	Assumption
                                         of Liability: To the extent permitted by applicable law, Recipient assumes all liability
                                         for damages that may arise from its use, storage, or disposal of the Material. University
                                         shall not be liable to Recipient for any loss, claim or demand made by the Recipient,
                                         or made against the Recipient by any other party, due to or arising from the use, storage
                                         or handling of the Material by Recipient, except to the extent caused by the gross negligence
                                         or willful misconduct of the University.

 

 

SECTION 8. PUBLICATION RIGHTS

 

		8.1	This Agreement shall not be interpreted to prevent or delay publication of
research resulting from the use of the Material or Modifications. Recipient shall have the right to publish and disclose the results
of the Research.

 

		8.2	In order to balance this right with the University's proprietary interests,
Recipient shall submit any proposed disclosure or publication to University for its review at least thirty (30) days prior to the
earlier of the date of submission to any journal for review or the date of publication or disclosure. University shall complete
its review within thirty (30) days of receipt of the submitted documents. University may require that Recipient delete from its
documents any reference to the University's confidential information.

 

		8.3	If, during the thirty
(30) day review period, University notifies Recipient that it desires to file a patent application on any Inventions disclosed
in the documents, Recipient will defer publication/disclosure for up to sixty (60) additional days from the date of submission
of the document to permit University to prepare and file a patent application. Recipient's Investigator agrees to provide copies
of research results related to the Material and appropriate acknowledgment of University as the source of the Material in all publications.

 

    	27 of 34

    	 

    

 

SECTION 9. TERM AND TERMINATION

 

		9.1	This Agreement shall terminate on the earliest of the following dates:

 

		a.	when the Material becomes generally available from third parties, for example,
through reagent catalogs or from a public repository;

 

		b.	on completion of Recipient's current research with the Material;

 

		c.	on thirty (30) days written notice by either party to the other; or

 

		d.	one year from the last signature date.

 

		9.2	If termination should occur as a result of 9.1(a),
Recipient shall be bound to the University by the least restrictive terms applicable to Material obtained from the then-available
sources.

 

		9.3	Upon termination of this Agreement, Recipient shall discontinue its use
of the Material and shall, upon direction of University, return or destroy any remaining Material. Recipient shall also either
destroy Modifications or remain bound by the terms of this Agreement as they apply to Modifications.

 

		9.4	In the event University terminates this Agreement for its convenience, University
will defer the effective date of termination for a period of up to one (1) year, upon request
from Recipient to complete research in progress.

 

 

SECTION 10. REIMBURSEMENT

 

		10.1	The Material is provided for a fee, which is solely to reimburse University
for its production and distribution costs. The amount of the fee_______ is U.S. dollars ($), due contemporaneously upon execution
of this Agreement. At the request of the University, Recipient shall provide its courier name and account number to University
in advance of distribution of Material. Courier Name: ______________ Billing account number: _______________

 

 

SECTION 11. CONFIDENTIALITY

 

		11.1	Recipient agrees to use reasonable efforts (which shall be at least as great
as the efforts to maintain the confidentiality of its own confidential information) to maintain the Material and information in
confidence, and to use the same only in accordance with this Agreement. Such obligation of confidentiality shall not apply to information
that Recipient can demonstrate:

 

		a.	was at the time of disclosure in the public domain;

 

		b.	has come into the public domain after disclosure through no fault of Recipient or its employees or agents;

 

 

 

    	28 of 34

    	 

    

 

		c.	was known to Recipient or its employees prior to disclosure thereof by University;

 

		d.	was lawfully disclosed to Recipient without prior obligation of confidence
University;by a third party that was not under an obligation of confidence to Recipient with respect thereto;

 

		e.	was independently developed without use of or reference to the confidential
material or

 

		f.	is required to be disclosed by law, government regulation, or court order,
and is disclosed only to the extent it satisfies that requirement.

 

		11.2	Recipient acknowledges that University is subject to the Colorado Open Records
Act (C.R.S. § 24-72-201, et seq.). All documents marked "Confidential" shall be treated by University as confidential
to the extent permitted under§ 24-72-204.

 

 

SECTION 12. GENERAL

 

		12.1	Assignment: This Agreement is
not assignable, whether by operation of law or otherwise, and sets forth the entire agreement and understanding of the parties
and cannot be changed or amended except by written agreement executed by both parties.

 

		12.2	Notice: Notice hereunder shall
be deemed sufficient if given by registered mail, postage prepaid, and addressed to the Party to receive such notice at the address
given below, or such other address as may hereafter be designated by notice in writing.

 

	 	University:	Recipient: 
	 	License Administrator	 
	 	Office of Technology Transfer	 
	 	University of Colorado, 588 SYS 	 
	 	Suite 100,4740 Walnut Street 	 
	 	Boulder, CO 80309	 

 

		12.3	Use of Names and Marks: Recipient
agrees not to identify University in any promotional advertising, press releases, sales literature or other promotional materials
to be disseminated to the public or any portion thereof without University prior written consent in each case, except that Recipient
may state that it has an agreement with University. Recipient further agrees not to use the name of University or any University
faculty member, inventor, employee or student or any trademark, service mark, trade name, copyright or symbol of University, without
the prior written consent of the University, entity or person whose name is sought to be used.

 

		12.4	Marking: Recipient agrees to:

 

 

    	29 of 34

    	 

    

 

		a.	Cause any products which may be sold as a result of this MTA to be marked
with the notice of the patent numbers or patent pending, as may be appropriate.

 

		b.	Comply with all laws and regulations of the United States and any other
country as appropriate concerning or controlling the import or export of the Licensed Products, data, software, laboratory prototypes
or other commodities. University makes no representation that a license or consent for export will not be required by applicable
governmental agencies, or if required, that it will be issued.

 

		c.	Comply with all applicable statutes, regulations, and guidelines, including
applicable governmental regulations, policies, and guidelines in its use of any University-supplied materials. Recipient agrees
not to use the materials for research involving human subjects or clinical trials in the United States without complying
with 21 C.F.R. Part 50 and 45 C.F.R. Part 46 (as those regulations may be amended from time to time). Recipient agrees not to
use the materials for research involving human subjects or clinical trials outside of the United States without notifying University
in writing, of such research or trials and complying with the applicable regulations of the appropriate national control authorities.
Written notification to University of research involving human subjects or clinical trials outside of the United States shall be
given no later than sixty (60) days prior to commencement of such research or trials.

 

		12.5	Compliance with the Law: Recipient
shall comply with all commercially material local, state, federal, and international laws and regulations relating to its obligations
under this Agreement regarding the development, manufacture, use, and sale of any products incorporating the Materials.

 

		12.6	Choice of Law: This Agreement shall
be governed by and construed in accordance with the laws of the State of Colorado.

 

		12.7	Dispute Resolution: In the event of
any dispute arising out of or relating to this Agreement, the affected Party shall promptly notify the other Party ("Notice
Date"), and the Parties shall attempt in good faith to resolve the matter.

 

		a.	Any disputes not so resolved shall be referred to senior executives, who
shall meet at a mutually acceptable time and location within thirty (30) days of the Notice Date and shall attempt to negotiate
a settlement.

 

		b.	If the senior executives fail to meet within thirty (30) days of the Notice
Date, or if the matter remains unresolved for a period of sixty (60) days after the Notice Date, the Parties hereby irrevocably
submit to the jurisdiction of a court of competent jurisdiction in the State of Colorado, and, by execution anddelivery of this
Agreement, each (i) accepts, generally and unconditionally, the jurisdiction of such court and any related appellate court, and
(ii) irrevocably waives any objection it may now or hereafter have as to the venue of any such suit, action or proceeding brought
in such court or that such court is an inconvenient forum.

 

 

    	30 of 34

    	 

    

 

		12.8	Merger and Modification of Agreement: The terms and
provisions contained in this Agreement constitute the entire Agreement between the Parties and shall supersede all previous communications,
representations, agreements or understandings, either oral or written, between the Parties hereto with respect to the subject matter
hereof, and no agreement or understanding varying or extending this Agreement will be binding upon either Party hereto, unless
in writing which specifically refers to this Agreement, signed by duly authorized officers or representatives of the respective
Parties, and the provisions of this Agreement not specifically amended thereby shall remain in full force and effect according
to their terms.

 

		12.9	Severability: The provisions and clauses of this Agreement
are severable, and in the event that any provision or clause is determined to be invalid or unenforceable under any controlling
body of the law, such invalidity or unenforceability will not in any way affect the validity or enforceability of the remaining
provisions and clauses hereof.

 

		12.10	Scope: This Agreement does not establish a joint venture,
agency, or partnership between the Parties, nor create an employer- employee relationship.

 

		12.11	Preservation of Immunity: The Parties agree that nothing
in this Agreement is intended or shall be construed as a waiver, either express or implied, of any of the immunities, rights, benefits,
defenses or protections provided to University under governmental or sovereign immunity laws from time to time applicable to University,
including, without limitation, the Colorado Governmental Immunity Act (C.R.S. § 24-10-101,
et seq.) and the Eleventh Amendment to the United States Constitution.

 

		12.12	Headings: Headings are included herein for convenience
only and shall not be used to construe this Agreement.

 

		12.13	Survival. The provisions of Sections 3 Inventions,
4 Commercial Use, 6 Warranties, Indemnifications and Insurance, 7 Recipient's Assumption of Liability, 8 Publication Rights, 11
Confidentiality, 12.11 Preservation of Immunity, 12.13 Survival, and any other provision of this Agreement that by its nature is
intended to survive, shall survive any termination or expiration of this Agreement.

 

 

    	31 of 34

    	 

    

 

IN WITNESS WHEREOF the
parties hereto have caused this Agreement, to be executed in duplicate by their respective duly authorized officers.

 

 

	University:	 	Recipient:
	 	 	 	 	 
	By:	 	 	By:	 
	Title:	 	 	Title:	 
	Date:	 	 	Date:	 

 

 

	Office of Technology Transfer 	 
	University of Colorado, 588 SYS 	 
	Suite 100, 4740 Walnut Street 	 
	Boulder, CO 80309	 

 

 

Recipient's Investigator:

 

___________________________________________

 

 

    	32 of 34

    	 

    

 

EXHIBIT A

 

Materials, Contact Information and Research Plan

 

Materials:

 

 

Amount of Materials to Be Provided:

 

Facilities Address:

 

	 	 	 	 
	 	 	 	 
	 	 	 	 

 

 

Investigator:

 

 

	 	Name:	 	 
	 	Title:	 	 
	 	 	 	 
	 	Address:	 	 
	 	 	 	 
	 	 	 	 
	 	Phone:	 	 
	 	Fax:	 	 
	 	Email:	 	 

 

	 	 	 	 
	 	Account Number of FedEx or DHL: _______________________________

 

 

Research Plan:

 

Title:

 

 

Aims:

 

 

Research Plan:

 

 

Anticipated Research Completion Date: _________________,
200__

 

 

    	33 of 34

    	 

    

 

 

EXHIBIT B

 

University describes
any preexisting obligations that University has to third parties (other than the federal government or non-profit foundations)
that would affect Recipient.

 

 

 

 

 

 

    	34 of 34Exhibit 10.14

 

CONSULTING SERVICES AGREEMENT

 

THIS CONSULTING SERVICES AGREEMENT (the "Agreement"), executed on the date signed below,
is effective as of October 1, 2009, and is entered into by and between Viral Genetics, Inc. a Delaware corporation with its executive
office located at 2290 Huntington Drive, Suite 100, San Marino, California 91108 (the "Company"), and JTL Enterprises
Corp, a New York corporation with its executive office located at 453 Half Hollow Road, Dix Hills, New York 11746 ("Consultant").
This agreement shall supersede in its entirety the prior agreement dated September 1, 2009. The terms "Party"
and "Parties" respectively refer to the Company and Consultant individually and collectively.

 

1. Services. The Company wishes to engage
Consultant to assist it in matters related to general ledger accounting, financial reporting and controls regarding its filing
requirements as may be required for the OTC Markets ("OTC") (formerly Pink Sheets OTC Market). Consultant shall act as
the Company's accounting expert as required in its management prepared financial statement submissions to the OTC. This agreement
shall apply to filings for the periods ended or ending September 30, 2009, December 31, 2009, March 31, 2010, June 30, 2010 and
September 30, 2010.

 

The following specific services (collectively,
the "Services") are to be provided by Consultant to the Company:

 

		·	Review of and/or recommendations for appropriate accounting policies and accounting for issuance of warrants and stock options
as stock compensation or in connection with other forms transactions(ie. mergers, acquisitions;

		·	Interface with Company management and consultants in preparing financial statements and compilation of other appropriate data;

		·	Preparation of financial statements and notes to financial statements in accordance with generally accepted accounting principles
required for inclusion periodic OTC;

		·	If necessary, interface with the Company's independent accountants in connection with the audit and/or review of the foregoing
statements and assistance to the Company in preparing and documentation for and assistance in the audit process, to the extent
mutually agreed between the parties;

		·	Assistance to the Company and its SEC or similar counsel in preparation of relevant sections of the initial disclosure statements
and periodic OTC filings, including dilution and capitalization tables, etc. Assistance, if requested, in drafting responses to
comment letters received as a result of such filings (if any) related to accounting and financial matters.

 

    	1

    	 

    

 

The
timely completion of the foregoing requires the participation and cooperation of the Company in providing the requisite information
on a timely basis.

 

The Company may also engage Consultant to
perform additional services not specifically mentioned above on mutually agreeable terms. These services could include, upon
its resuming filing with the SEC, assistance in documenting or establishing compliance with the requirements of
Sarbanes-Oxley Act related to internal controls over financial reporting.

 

2.Fees and Expenses. Compensation
included in this paragraph for the Services are based upon the Consultant's and his of associates' actual hours incurred or to
be incurred at actual hourly billing rates with an appropriate discount. Other than incidental amounts, out-of-pocket and travel
expenses shall be approved by the Company in advance and the Consultant shall be reimbursed upon invoice. Based upon prior experience
with Viral Genetics, Inc. and similar companies, and assuming current accounting functions continue to be performed by the Company's
management and other consultants, it is estimated that the following fees will represent fair compensation to Consultant, his
employees and agents for the foregoing Services (consisting of financial statements relating to 4 quarterly reports and an annual
report). Services related to the period ended September 30, 2009 have been completed and Services relating to the year ended December
31, 2009 are in process. The structure of the compensation herein recognizes the need for these Services by the Company during
a period where its cash flow may be limited. Consultant acknowledges that cash payments received to date satisfy cash retainers
through December 31, 2009. Consultant shall be entitled to the following additional compensation — (i) and average of $3,000
per month for each of the 12 months in the period ending December 31, 2010, with a scheduled initial payment of $9,000 by March
31, 2010. This payment corresponds to payment for January 2010, February 2010 and March 2010. In the event, however, that the
Company's cash flow is not adequate for part or all of these payments in the judgment of the Company, than Consultant may elect
to accept payment in restricted shares of the Company based upon a conversion price of $0.03 per share and warrants exercisable
for a five-year period to purchase an equal number of common shares of the Company at $0.04 per share. In that event, the Company
shall cause share certificates and appropriate warrants to be issued within 10 days of notice by Consultant, plus (ii) effective
as of the October 1, 2009, 2 million shares of restricted common stock of the Company and warrants to purchase an additional 2
million common shares of the Company for a period of 5 years priced as follows: (A) 500,000 shares at $0.03 per share, (B) 1,000,000
shares at $0.05 per share and (C) 500,000 shares at $0.06 per share Certificates for these common shares and formal warrants
agreements shall be issued within 10 days of the execution by the parties of this Agreement.

 

3.Successors and Assigns. This Agreement
is binding upon and inures to the benefit of the Parties and their respective affiliates, successors and assigns; provided
however, that in no event shall Consultant's obligations to perform the Services be delegated or transferred by Consultant
without the prior written consent of the Company.

 

4.Term. This Agreement shall commence
on the date hereof and continue for the period of the Services as defined above. Upon completion of these services, the Agreement
may be extended on terms mutually agreeable to both parties. It can be terminated in accordance with the provisions of Section
5 hereof. This Agreement may be modified on mutually agreeable terms in writing.

 

    	2

    	 

    

5.Termination. (i) Either Party
may terminate this Agreement on at least thirty (30) days prior written notice; provided, however, if Consultant,
or any of its employees or other persons it engages to provide the Services, violate any of the provisions of this Agreement or
engage in any criminal activity, the Company may immediately terminate this Agreement without providing said written notice. In
the event of termination, the Parties shall finalize any billing based upon the amount of monthly billing specified in 2(i) through
the date that services were provided and shall be payable immediately in the manner described in 2 (i). (ii) Nonpayment of Consultant's
invoices in accordance with Paragraph 2 hereof shall be cause for termination by Consultant if such invoices are not paid in the
accordance with 2 (i) and 2 (ii) within ten business days of notice to the Company.

 

6.Independent Contractor Relationship.
The relationship of the Company to Consultant shall be that of contractor dealing at arm's length. Nothing contained in this Agreement
shall be construed to place them in the relationship of partners, principal and agent, employer/employee or joint venturers.
Consultant shall pay all applicable self-employment taxes for its employees or other persons it engages and will indemnify, defend
and hold the Company harmless against all taxes or other contributions, costs, claims, penalties, interest, expenses or proceedings
arising out of or in connection with such taxes and contributions. Neither Party shall have the power or right to bind or obligate
the other Party.

 

7.Limitation of Liability Except
as otherwise set forth herein, neither Party shall be liable for any special, incidental, indirect, consequential or punitive
damages, including loss of profits, loss of business opportunity, or other economic loss, whether arising in contract or tort
(including negligence), claimed to have been sustained by a Party directly or indirectly, as a result of or arising pursuant to
this Agreement. Except for claims (including claims of personal injury, death, or property damage) caused by Consultant's bad
faith, willful or wanton misconduct, gross negligence or recklessness, or a breach of Consultant's obligations under the paragraph
captioned "Confidentiality," Consultant shall not be liable to the Company for damages in excess of the fees received
by Consultant. The foregoing limitations shall apply even if Consultant is advised of the possibility of such damages or losses.

 

8.Indemnification.
The Company shall indemnify, defend and hold harmless the Consultant from and against any and all losses, damages, liabilities,
reasonable attorney's fees, court costs and expenses resulting or arising from any third-party claims, actions, proceedings, investigations
or litigation relating to or arising from or in connection with any act or omission by the Company, including with respect to
any filings by the Company with the SEC, the Pink Sheets markets or any other authority. The indemnification specified in the
foregoing sentence shall also apply to Consultant in his role as an accounting expert for the Company. Consultant shall indemnify,
defend and hold harmless the Company from and against any and all losses, damages, liabilities, reasonable attorney's fees, court
costs and expenses resulting or arising from any third-party claims, actions, proceedings, investigations or litigation relating
to or arising from or in connection with Consultant's bad faith, willful or wanton misconduct, gross negligence or recklessness
in performing the Services.

 

    	3

    	 

    

 

9.Notice. For the purpose of this
Agreement, notices and all other communications provided for herein shall be in writing and shall be deemed to have been duly
given: (i) when delivered, if personally delivered; (ii) when sent by facsimile transmission, when receipt therefore has been
duly received; or (iii) when mailed by United States registered mail, return receipt requested, postage prepaid, or sent by recognized
overnight courier, addressed as set forth in the preamble to this Agreement or to such other address as a Party may have furnished
to the other in any writing in accordance herewith, except that notices of change of address shall be effective only upon receipt.

 

10.Miscellaneous. No provision of
this Agreement may be modified, waived or discharged unless such waiver, modification or discharge is agreed to in writing signed
by an authorized officer of each Party. No agreements or representations, oral or otherwise, express or implied, with respect
to the subject matter hereof have been made by either Party, which are not set forth expressly in this Agreement. The validity,
interpretation, construction and performance of this Agreement shall be governed by the laws of the State of New York. Except
for controversies arising under Section 13 hereof; the Parties hereby irrevocably agree to waive trial by jury and that any controversy
arising under or in relation to this Agreement shall be resolved by binding arbitration in the City of New York in accordance
with the laws of the State of New York and the rules then in effect of the American Arbitration Association using a single, neutral
arbitrator. The prevailing party in any court or arbitration proceeding hereunder shall be entitled to reimbursement of its fees,
costs and expenses incurred therein, including those of its attorneys.

 

11.Severability. If in any jurisdiction,
any provision of this Agreement or its application to any Party or circumstance is restricted, prohibited or unenforceable, such
provision shall, as to such jurisdiction, be ineffective only to the extent of such restriction, prohibition or unenforceability,
without invalidating the remaining provisions hereof and without affecting the validity or enforceability of such provision in
any other jurisdiction or its application to other persons or circumstances. In addition, if any one or more of the provisions
contained in this Agreement shall for any reason in any jurisdiction be held to be excessively broad as to time, duration, geographical
scope, activity or subject, it shall be construed, by limiting and reducing it, so as to be enforceable to the extent compatible
with the applicable law of such jurisdiction as it shall then appear.

 

12.Representations and Warranties
of Consultant and the Company. Consultant hereby represents and
warrants that: (i) it has the knowledge and skill, and possesses all necessary licenses, permits and authorizations required
to provide the Services; (ii) Consultant shall exert reasonable efforts to perform the Services on a timely basis; (iii) it
has the full and unrestricted right and authority to enter into and perform this Agreement; (iv) entering into and performing
this Agreement does not and shall not breach or violate or conflict with any provision of any agreement or understanding,
oral or written, between Consultant and any third party; and (v) The Company hereby represents and warrants it will cooperate
and provide Consultant with: (a) all requested information on a timely basis; (b) all information, documents and disclosures
that the Company has knowledge of or should have knowledge of that would be necessary for Consultant to perform hereunder;
and (c) and specifically the Company and its management have and will specifically advise Consultant of all matters of which
they are aware that would be necessary for the preparation of its financial statements by Consultant in accordance
with generally accepted accounting principles.

    	4

    	 

    

 

 

13. Confidentiality. Consultant understands
and agrees that in the course of the engagement with the Company, it will receive and become aware of confidential and proprietary
information, projects, practices, customer contacts, potential customers, methodologies and management philosophy relating to
the Company's business (the "Confidential Information"). Consultant hereby acknowledges the sensitivity
and confidential nature of the Confidential Information and covenants and agrees to keep all such Confidential Information strictly
confidential. In this regard, Consultant shall not at any time or in any manner, either directly or indirectly, divulge, disclose,
communicate, or use the Confidential Information it obtains or is otherwise exposed to or becomes aware of as a result of its
engagement by the Company in any manner not expressly authorized by the Company in writing. Consultant understands and agrees
that its obligation regarding the confidentiality of the Confidential Information shall continue for so long as such Confidential.
Information remains confidential.

 

The obligation of confidentiality shall not
apply to any Confidential Information: (i) which was already known to Consultant at the time of disclosure and Consultant promptly
informs the Company thereof; (ii) which was already in the public domain; (iii) which becomes available to the public through no
fault of Consultant; (iv) which is disclosed to others by the Company without restriction as to disclosure and/or commercial use;
or (v) which is required to be disclosed by Consultant in response to an effective subpoena, administrative or court order, or
other valid legal process but then only to the extent necessary to comply therewith.

 

Upon
termination of this Agreement and upon request by the Company, Consultant will promptly return to the Company all documents, records
or other items belonging to the Company, whether prepared by Consultant or furnished to it by the Company, or otherwise, and relating
in any way to the business or Confidential Information of the Company.

 

IN WITNESS WHEREOF, and intending to be legally
bound, this Agreement has been executed by the Company and Consultant as of the date first written above.

 

Viral Genetics, Inc.

 

By: /s/ Haig Keledjian     Date
march 18, 2010

Name and Title: Haig
Keledjian, President

 

 

JTL Enterprises Corp.

 

By: Myron W. Landin     Date
March 18, 2010

Name and Title: Myron
W. Landin CPA, President

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00232-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00232-of-00352.parquet"}]]